Sildenafil Citrate Tablet, Film Coated
Product Images NDC 52817-295

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 52817-295). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Trupharma Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (20 mg Tablet Bottle Label)

This is a medication with sildenafil citrate USP, equivalent to 20 mg sildenafil per film-coated tablet. It should be stored at 20°C-25°C but can tolerate excursions to 15°C-30°C. It should be dispensed in tight containers and is only available through prescription. The medication is manufactured by Rubicon Research Private Limited and distributed by TruPharma, LLC. Patient information is available on the website www.trupharma.com. Keep out of reach of children.*

FDA Label Image

Principal Display Panel (20 mg Tablet Bottle Label)

This is a description of sildenafil citrate tablets that contain 20mg of sildenafil. The tablets are film-coated and should be stored between 20°C-25°C (68°F-77°F) with permitted excursions up to 15°C-30°C (59°F-86°F). The tablets should be dispensed in tight containers and kept out of reach of children. The tablets are distributed by TruPharma, LLC and manufactured by Rubicon Research Private Limited in Maharashtra, India. The patient information sheet is available on the website www.trupharma.com.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 06)

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 07)

This text appears to be a chart presenting recommendations for adjusting drug doses based on the interaction fold change and 90% confidence interval. It includes information for specific drugs, their AUC, Cmax, and nodose adjustments. The chart also includes a reference to the change relative to Sildenafil alone and mentions exercise capacity benefits or lack thereof when adding skienafl to bosentan therapy.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 08)

This is a drug interaction table that shows the effects of Acenocoumarol when taken with other drugs. The table indicates whether or not a dose adjustment is recommended based on the fold change and 90% confidence interval. There are also notes on the study of the effects of certain drugs on patient's exercise capacity.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 09)

This is a table showing the change from baseline in meters for various weeks of a study involving different doses of sildenafil (20mg, 40mg, and 80mg) and a placebo. The table is not complete and doesn't provide any context or explanation for the study.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 10)

This seems to be a medical research report related to idiopathic Pulmonary Arterial Hypertension (PAH) treatment. The report discusses the effectiveness of Sildenafil, a medication used for PAH, with dosage mentioned as 20 mg TID. The results show a placebo-corrected change in a 6-minute walk distance in meters by patients with PAH who were given Sildenafil. Apart from this, patient data is also mentioned, which includes age, gender, and medical history.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 11)

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 12)

FDA Label Image

Structure Formula (Sildenafil Tablets Usp 20mg Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.